News

Following recent acquisitions in Croatia and Romania, the purchase of Armila is said to represent the latest stage in Anzag’s strategy to establish itself in carefully targeted high-growth

To date, Chelsea has enrolled 147 of the planned 200 patients for this 12-week, four-arm, parallel group trial comparing 0.25mg, 0.5mg and 1mg once daily oral doses of

Under the terms of the agreement, clinical researchers from University of California, San Diego (UCSD) will perform the Phase IIa study at the University’s General Clinical Research Center,

Dr Goldberg previously served as president of clinical research services and perceptive informatics at Parexel. Dr Goldberg will continue to oversee these areas of the company and report

As part of the transaction, a subsidiary of Brookfield Asset Management the holder of approximately 60% of the outstanding common shares of MediSolution has entered into an agreement

The company has agreed to sell 1.13 million shares of common stock and the selling stockholders have agreed to sell the remaining 2.36 million shares of common stock.

The Phase II, double-blinded placebo controlled 12-week dosing trial will enroll approximately 90 patients who are stable on metformin treatment only, the current first-line therapy for type 2

Following validation by Proteome Systems of data generated by Egenix, which demonstrated increased expression of HCA (human carcinoma antigen) in cancerous versus non-cancerous prostate tissues, the proof of

Previously, BioSante received a special protocol assessment (SPA) for LibiGel’s use in ‘surgically’ menopausal women. Stephen Simes, BioSante’s president & CEO, said: “With our two SPAs and meeting